• In June 2026, National HealthCare Corporation (NYSEAM:NHC) was added to multiple Russell growth indexes, including the Russell 2000 Growth, Russell 2500 Growth, Russell 3000 Growth, Russell 3000E Growth, Russell 2000 Growth-Defensive, and Russell Small Cap Comp Growth benchmarks.
• These index additions broaden National HealthCare’s exposure to passive and benchmark-driven investors, potentially increasing its visibility and liquidity within the small- and mid-cap healthcare space.
• Next, we will examine how National HealthCare’s inclusion in several Russell growth benchmarks influences its investment narrative and perceived growth profile.

Find 41 companies with promising cash flow potential yet trading below their fair value.

What Is National HealthCare's Investment Narrative?

For someone considering National HealthCare, the core belief is that a mature, profitable operator in post-acute and senior care can still create value through disciplined expansion and steady execution rather than dramatic transformation. The planned, debt-funded acquisition of assets from National Health Investors is the key near term catalyst, with the new US$475.0 million term loan and US$50.0 million revolver set to reshape the balance sheet and capital allocation priorities. Inclusion across several Russell growth indices in June 2026 plugs NHC into a wider universe of passive and benchmark-aware buyers, but the recent share price strength suggests the direct impact on the business is more about improved liquidity than fundamentals. The bigger risks remain integration of the NHI assets, higher leverage, and rich valuation multiples after a very strong multi year run.

However, investors should be aware of how higher debt and insider selling could affect the story. National HealthCare's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for NHC range from about US$122.63 to roughly US$636.06, showing how far apart individual views can be. When you set those against the recent index inclusions and the upcoming, highly financed NHI asset purchase, it becomes clear that differing opinions on balance sheet risk and growth potential can lead to very different conclusions about the company’s future performance. Consider exploring several of these perspectives before deciding how NHC fits into your portfolio.

Explore 3 other fair value estimates on National HealthCare - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your National HealthCare research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free National HealthCare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate National HealthCare's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.